A process for preparing a glycoside compound represented by formula (3), which includes reacting a glycoside compound represented by formula (1) with an ether compound represented. by formula (2) in the presence of an. oxidizing agent and an acid to prepare a glycoside compound represented by formula (3),

##STR00001## where the oxidizing agent is added to a reaction system, followed by adding an acid thereto, where B.sup.a represents a cytosine group which may be optionally substituted with acyl group, or an uracil group, R.sup.1 represents a C1 to C6 alkyl group or a phenyl group, and n is 0 or 1, where an oxidizing agent is selected from N-halogenated succinimide and N-halogenated hydantoin, and an acid is selected from perfluoroalkylcarboxylic acid, alkylsulfonic acid, arylsulfonic acid, periluoroalkylsulfonic acid, and salts thereof, and any combinations thereof, which can provide a synthesis of a desired compound with high purity.

Borocarbohydrate complex containing compositions are presented that have an improved di-complex to boric acid ratio. In some embodiments, compositions are characterized by a di-complex to boric acid ratio of at least 5:1 and more typically at least 10:1 in liquid form, and at least 20:1 in dried form. In other embodiments, compositions are characterized by a minimum content of 80 wt % di-complex and a boric acid content of less than 15 wt %, and more typically less than 5 wt %. Contemplated compositions are thought to have improved biological activity and reduced content of undesired components.

Borocarbohydrate complex containing compositions are presented that have an improved di-complex to boric acid ratio. In some embodiments, compositions are characterized by a di-complex to boric acid ratio of at least 5:1 and more typically at least 10:1 in liquid form, and at least 20:1 in dried form. In other embodiments, compositions are characterized by a minimum content of 80 wt % di-complex and a boric acid content of less than 15 wt %, and more typically less than 5 wt %. Contemplated compositions are thought to have improved biological activity and reduced content of undesired components.

The present invention provides an efficient process for preparing a nucleic acid oligomer, that is, a process for preparing a nucleic acid having a phosphate triester bond effectively by oxidizing a nucleic acid precursor having a phosphite triester bond. Also the present invention provides a process for preparing a nucleic acid compound having at its 5′-terminus a nucleotide represented by formula (I) by a phosphoramidite method, which comprises a step of reacting a precursor having a phosphite triester bond represented by a formula (II) (the definitions of substituents of formulae (I) and (II) are described in the Description) with an oxidation solution which contains iodine, pyridine and water, and a molar ratio of iodic acid to iodine (mole of iodic acid/mole of iodine) is 30×10.sup.−3 or less.

##STR00001##

Disclosed herein, inter alia, are silicon containing detectable compounds and methods of use thereof.

The present disclosure relates to a compound of formulae (I) or (II), or a pharmaceutically acceptable salt, a solvate, a hydrate thereof, a pharmaceutical composition comprising a compound of formulae (I) or (II), and use thereof, wherein various Markush groups are as described herein. ##STR00001##

The present disclosure provides 3′ protected nucleotides, including those 3′ protected nucleotides having a detectable tag. Systems and methods of sequencing nucleic acids using the 3′ protected nucleotides are also disclosed, such as the sequencing of a nucleic acid using a nanopore or the sequencing of a nucleic acid via sequencing-by-synthesis.

Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO.sub.2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

To provide novel compounds that are promising as prodrug-type anticancer agents, a compound represented by general formula (I) or a salt thereof is provided. ##STR00001##

To provide novel compounds that are promising as prodrug-type anticancer agents, a compound represented by general formula (I) or a salt thereof is provided. ##STR00001##